Potential pitfalls on the road to an effective HIV vaccine.
Experimental vaccines for AIDS prophylaxis are being tested in larger and higher-risk populations. Here, David Schwartz, an advocate of HIV-vaccine research and development, highlights some of the concerns that have been voiced about this strategy and presents a simple mathematical model that considers the drawbacks to vaccine-induced expansion of HIV-specific CD4+ T cells.